475P A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)
Jordan Berlin(Dana-Farber Cancer Institute), Sarah P. Blagden(Churchill Hospital), Michelle Myers(Nucana (United Kingdom)), Aimery de Gramont(Institut Hospitalier Franco Britannique), Andrew L. Coveler(University of Washington), Farasat Kazmi(University of Oxford), Jeffrey W. Clark(Massachusetts General Hospital), Janet Graham(Beatson West of Scotland Cancer Centre), Mary Linton B. Peters(Beth Israel Deaconess Medical Center), T. R. J. Evans, Kristen K. Ciombor(The Ohio State University)
Cited by 1
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k